指南与共识肾癌与肾肿瘤

欧洲泌尿外科学会肾细胞癌指南更新:纳武利尤单抗联合卡博替尼加入免疫检查点抑制剂联合治疗用于初治转移性透明细胞肾细胞癌

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
指南 / 共识 · Eur Urol · 2020-12-24

基于CheckMate 9ER等III期随机对照试验的新数据,EAU肾细胞癌指南更新推荐:在晚期透明细胞肾细胞癌一线治疗中,继续推荐酪氨酸激酶抑制剂联合免疫检查点抑制剂(IO)用于各IMDC风险组;IMDC中/低危患者推荐伊匹木单抗联合纳武利尤单抗双免疫治疗。

要点

  • 卡博替尼联合纳武利尤单抗在初治转移性透明细胞肾细胞癌中显示PFS和OS获益。
  • 帕博利珠单抗联合阿昔替尼在ITT人群中持续OS获益,各IMDC亚组均见PFS获益。
  • 伊匹木单抗联合纳武利尤单抗在IMDC中/低危患者中确认长期获益。

核心结论

  • 指南继续推荐酪氨酸激酶抑制剂联合免疫检查点抑制剂用于晚期一线肾细胞癌各IMDC风险组。
  • IMDC中/低危患者推荐伊匹木单抗联合纳武利尤单抗双免疫治疗。

研究设计与样本

  • EAU肾细胞癌指南小组基于III期随机对照试验的新数据更新推荐。

主要发现

  • CheckMate 9ER显示卡博替尼联合纳武利尤单抗改善PFS和OS。
  • Keynote-426更新显示帕博利珠单抗联合阿昔替尼在ITT人群持续OS获益,各IMDC亚组PFS获益。
  • CheckMate 214更新确认伊匹木单抗联合纳武利尤单抗在IMDC中/低危患者的长期获益。

临床怎么用

  • 晚期透明细胞肾细胞癌一线治疗可选择酪氨酸激酶抑制剂联合免疫检查点抑制剂。
  • IMDC中/低危患者可选用伊匹木单抗联合纳武利尤单抗双免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. PATIENT SUMMARY: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bedke J, Albiges L, Capitanio U, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol. 2020. PMID: 33357997. doi:10.1016/j.eururo.2020.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。